About Us
The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research program at the University of Oxford. The OPDC was established in February 2010 and brings together internationally-renowned scientists who work on the genetics of Parkinson’s, the generation of cell and animal models, and the wiring of brain circuits which control movement, with clinical experts in the diagnosis and treatment of Parkinson’s.
Our world-class research centre works to understand the earliest events in the development of Parkinson’s with an ultimate view to target the molecular mechanisms of disease with neuroprotective therapies to prevent disease onset or delay progression.
Our program is focused on the molecular pathways to Parkinson’s in order to:
- Understand the progression of Parkinson’s
- Predict the onset of Parkinson’s
- Identify potential drug targets for Parkinson’s
- Develop new treatments that will prevent the development of Parkinson’s in at-risk individuals.
Watch the video below to learn more about OPDC's research:
Latest News
Upcoming Seminars
Latest publications
-
Mitochondrial dysfunction and mitophagy defects in LRRK2-R1441C Parkinson's disease models.
Journal article
Williamson MG. et al, (2023), Hum Mol Genet, 32, 2808 - 2821
-
Axo-glial interactions between midbrain dopamine neurons and oligodendrocyte lineage cells in the anterior corpus callosum.
Journal article
Caldwell M. et al, (2023), Brain Struct Funct
-
Discovery of CVN417, a Novel Brain-Penetrant α6-Containing Nicotinic Receptor Antagonist for the Modulation of Motor Dysfunction.
Journal article
Christie LA. et al, (2023), J Med Chem
-
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson's disease.
Journal article
Martinez-Carrasco A. et al, (2023), NPJ Parkinsons Dis, 9
-
Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study.
Journal article
Joza S. et al, (2023), Brain, 146, 3258 - 3272
-
Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials.
Journal article
Street D. et al, (2023), Brain, 146, 3232 - 3242